US2023398225A1PendingUtilityA1

Pd-l1/sting conjugates and methods of use

Assignee: INCYTE CORPPriority: Nov 21, 2018Filed: Jan 3, 2023Published: Dec 14, 2023
Est. expiryNov 21, 2038(~12.3 yrs left)· nominal 20-yr term from priority
A61K 31/506C07D 471/04A61K 31/4439A61K 47/65A61K 31/437A61P 35/00A61K 31/4184A61K 47/60A61K 31/519A61K 47/55A61K 47/545C07D 519/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.

Claims

exact text as granted — not AI-modified
1 . A compound of Formula (I):
   P-L-S  (I)
   or a pharmaceutically acceptable salt thereof, wherein P is a ligand that binds to cell surface PD-L1 protein and induces PD-L1 internalization, L is a linking group, and S is a moiety that agonizes STING.   
     
     
         2 .- 31 . (canceled)

Join the waitlist — get patent alerts

Track US2023398225A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.